Sabby Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Sabby Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1,969	Closed	-$17.3M	–	223
2017 Q1	$17.3M	Buy	+1,969	New	+$175K	0.93%	19
2016 Q1	–	Sell	-1,308	Closed	-$13.7M	–	309
2015 Q4	$13.7M	Sell	1,308 -1,067	-45%	-$111K	0.75%	19
2015 Q3	$25M	Sell	2,375 -1,421	-37%	-$190K	1.03%	15
2015 Q2	$51.9M	Buy	3,796 +1,635	+76%	+$203K	1.89%	8
2015 Q1	$26.9M	Buy	2,161 +1,238	+134%	+$131K	1.12%	19
2014 Q4	$8.34K	Buy	+923	New	+$76.8K	0.26%	50
2013 Q4	–	Sell	-417	Closed	-$3.01M	–	225
2013 Q3	$3.01M	Buy	+417	New	+$27.7K	0.2%	66

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sabby Management's BMRN Position: Q4 2015 in Review

Sabby Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2015, closing a stake of 174,073 shares — an estimated $18.2M sold.

Sabby Management first reported a position in BMRN in Q4 2014 and held it in 2 quarters. The position peaked at $18.3M in Q3 2015. 388 funds tracked by Wall St. Rank hold BMRN as of Q4 2015.

Sabby Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
Sabby Management sold 174,073 BioMarin Pharmaceuticals shares in Q4 2015, an estimated $18.2M.
Sabby Management first reported a position in BioMarin Pharmaceuticals in Q4 2014 and held it in 2 quarters.
Sabby Management's BioMarin Pharmaceuticals position peaked at $18.3M in Q3 2015.
388 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2015.

Based on Sabby Management's 13F filing for Q4 2015, filed 16 Feb 2016.